Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3245467

Cc1cnc(NCCc2ccc3c(c2)OCO3)c(=O)n1CC(=O)NCCONC(=N)N.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
F2 P00734 19/20 0.55
PRSS1 P07477 14/20 0.55
PRSS2 P07478 10/20 0.55
PRSS3 P35030 10/20 0.55
F10 P00742 1/20 0.47
PLAT P00750 1/20 0.47
MASP2 O00187 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242906 0.95 F2 (0.59) F2PRSS1PRSS2PRSS3MASP2
Trifluoroacetic Acid SCHEMBL3235273 0.88 F2 (0.59) F2PRSS1PRSS2PRSS3F10
Trifluoroacetic Acid SCHEMBL3268440 0.87 F2 (0.64) F2PRSS1PRSS2PRSS3F10
Trifluoroacetic Acid SCHEMBL3249518 0.87 F2 (0.71) F2PRSS1PRSS2PRSS3F10
Trifluoroacetic Acid SCHEMBL3242723 0.87 F2 (0.70) F2PRSS1PRSS2PRSS3F10
Trifluoroacetic Acid SCHEMBL3249500 0.87 F2 (0.69) F2PRSS1PRSS2PRSS3F10
Trifluoroacetic Acid SCHEMBL3242113 0.87 F2 (0.63) F2PRSS1PRSS2PRSS3F10
Trifluoroacetic Acid SCHEMBL3246675 0.86 F2 (0.74) F2PRSS1PRSS2PRSS3F10
Trifluoroacetic Acid SCHEMBL3261368 0.86 F2 (0.58) F2PRSS1PRSS2PRSS3F10
Trifluoroacetic Acid SCHEMBL3262376 0.85 F2 (0.70) F2PRSS1PRSS2PRSS3F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1589029-B1 Pyrazinone protease inhibitors ORTHO MCNEIL PHARM INC (US) 2010-03-17 EP disclosed
EP-1589029-A2 Pyrazinone protease inhibitors Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) 2005-10-26 EP disclosed
EP-1086122-B1 PYRAZINONE PROTEASE INHIBITORS JOHNSON & JOHNSON PHARM RES (US) 2005-08-24 EP disclosed
US-6514978-B2 Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-02-04 US disclosed
US-20010021713-A1 Thromboresistant materials incorporating pyrazinone protease inhibitors LU TIANBAO (US) 2001-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021713-A1 Thromboresistant materials incorporating pyrazinone protease inhibitors HPN, SERPINE1, SERPINC1 F2 23/4885PRSS1 10/4885PRSS2 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.